ADAPT: The first study examining the long-term effects of COVID-19

Share

Share on facebook
Share on twitter
Share on linkedin
St Vincent's Clinic Foundation at Darlinghurst, Sydney, Australia

ADAPT is an important study in Australia, and internationally, launched at the onset of the pandemic and rapidly scaling up to follow around 200 patients post COVID-19 infection (inpatients and community-based) as well as a community control cohort (ADAPT-C)

Since May 2020 it has been following patients diagnosed with Long Covid (LC) who continue to have symptoms such as breathing and fatigue problems lasting longer than 12 weeks after infection, comparing their immune response, lung function and muscle strengths as well as their psychological wellbeing with people of similar age who are fully recovered.

Outcomes from this research are helping our leading Australian researchers and clinicians understand the true, medium to long-term impact of COVID-19 and have led to unique insights around the immunological ‘signature’ of Long COVID. This work, arising from ADAPT and performed in collaboration with investigators at the Kirby Institute has recently been published in the highly prestigious journal ‘Nature Immunology’ https://www.nature.com/articles/s41590-021-01113-x

St Vincent’s Clinic Foundation was delighted to make these grants totalling AUD$150,000 available at short notice and help kick-start this study.

ADAPT continues to follow and enrol people from subsequent waves including the Delta and Omicron outbreaks, ensuring future findings from the study continue to provide valuable insights as the next stage of this pandemic unfolds.

St Vincent’s Clinic Foundation was delighted to make these grants totalling AUD$150,000 available at short notice and help kick-start this study.

“We are incredibly grateful for the support of our study from the St Vincent’s Clinic Foundation. This grant is a very significant contribution to our endeavours to answer the most relevant questions related to COVID-19 in the St Vincent’s patient population,” said Prof Gail Matthews (co-PI of ADAPT with Dr David Darley).

“The willingness of our COVID-19 patients to be involved in these research studies has been extremely encouraging. This support now provides us with the capacity to optimise that enthusiasm to advance our understanding of COVID-19,” said Prof Gregory Dore (PI ADAPT-C).